Alterola Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Selling, General & Admin	2.49	2.08	1.85	6.13	0.31
Research & Development	0.06	0.03	0.18	0.34	-
Operating Expenses	2.55	2.11	2.03	6.47	0.31
Operating Income	-2.55	-2.11	-2.03	-6.47	-0.31
Currency Exchange Gain (Loss)	0.07	0.03	-0.02	-	-
Other Non Operating Income (Expenses)	-0.04	-0.04	-0.02	0	-
EBT Excluding Unusual Items	-2.86	-2.12	-2.07	-6.47	-0.31
Asset Writedown	-0.39	-0.39	-	-	-
Other Unusual Items	0.28	0.14	-	-	-
Pretax Income	-2.97	-2.37	-2.07	-6.47	-0.31
Net Income	-2.78	-2.37	-2.07	-6.47	-0.31
Net Income to Common	-2.78	-2.37	-2.07	-6.47	-0.31
Shares Outstanding (Basic)	1,375	1,052	807	770	-
Shares Outstanding (Diluted)	1,375	1,052	807	770	-
Shares Change (YoY)	70.86%	30.31%	4.82%	-	-
EPS (Basic)	-0.00	-0.00	-0.00	-0.01	-
EPS (Diluted)	-0.00	-0.00	-0.00	-0.01	-
EBIT	-2.55	-2.11	-2.03	-6.47	-0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.